[go: up one dir, main page]

PE20191819A1 - Analogos de deutetrabenazina, su preparacion y uso - Google Patents

Analogos de deutetrabenazina, su preparacion y uso

Info

Publication number
PE20191819A1
PE20191819A1 PE2019001871A PE2019001871A PE20191819A1 PE 20191819 A1 PE20191819 A1 PE 20191819A1 PE 2019001871 A PE2019001871 A PE 2019001871A PE 2019001871 A PE2019001871 A PE 2019001871A PE 20191819 A1 PE20191819 A1 PE 20191819A1
Authority
PE
Peru
Prior art keywords
deutetrabenazine
analogs
preparation
compound
methods
Prior art date
Application number
PE2019001871A
Other languages
English (en)
Inventor
Jim Kerr
Chengzi Zhang
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of PE20191819A1 publication Critical patent/PE20191819A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Referido a una composicion farmaceutica, que comprende una mezcla de sustancia farmacologica deutetrabenazina y un vehiculo farmaceuticamente aceptable; en donde la sustancia farmacologica deutetrabenazina comprende 0.5 % o menos del compuesto 1 y 0.15 % o menos de compuesto 2; y donde esta composicion farmaceutica es estable cuando se almacena a temperatura ambiente entre 1 y 24 meses. Estos analogos de deutetrabenazina son inhibidores del transportador vesicular de monoamina 2 (VMAT2). Ademas, esta composicion se encuentra en una forma de dosificacion unitaria oral, metodos de preparacion, metodos para detectar los mismos en composiciones que comprenden deutetrabenazina.
PE2019001871A 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso PE20191819A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
PE20191819A1 true PE20191819A1 (es) 2019-12-27

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001871A PE20191819A1 (es) 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso

Country Status (20)

Country Link
US (4) US11813232B2 (es)
EP (1) EP3596077A1 (es)
JP (3) JP7608050B2 (es)
KR (2) KR20230003308A (es)
CN (1) CN110709398A (es)
AR (1) AR111182A1 (es)
AU (2) AU2018236336B2 (es)
BR (1) BR112019018966A2 (es)
CA (1) CA3056612A1 (es)
CL (1) CL2019002629A1 (es)
CO (1) CO2019011271A2 (es)
EA (1) EA201992168A1 (es)
IL (1) IL269132A (es)
MX (1) MX2019010913A (es)
PE (1) PE20191819A1 (es)
SG (1) SG11201908477QA (es)
TW (1) TWI772382B (es)
UA (1) UA127052C2 (es)
WO (1) WO2018170214A1 (es)
ZA (1) ZA201906326B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування
WO2020123900A1 (en) 2018-12-13 2020-06-18 Auspex Pharmaceuticals, Inc. Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
PT4153136T (pt) * 2020-06-10 2024-03-22 Auspex Pharmaceuticals Inc Formas de dosagem osmótica que compreendem deutetrabenazina e métodos de utilização da mesma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
ES2652289T3 (es) 2008-09-18 2018-02-01 Auspex Pharmaceuticals, Inc. Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
CN104744456A (zh) 2010-06-01 2015-07-01 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CN116768882A (zh) 2012-09-18 2023-09-19 奥斯拜客斯制药有限公司 化合物、及其药物组合物及治疗方法
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
MX369956B (es) 2013-12-03 2019-11-27 Auspex Pharmaceuticals Inc Metodos para preparar compuestos de benzoquinolina.
US20160287574A1 (en) 2015-03-06 2016-10-06 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
UA127052C2 (uk) 2017-03-15 2023-03-29 Оспекс Фармасьютікалс, Інк. Аналоги деутетрабеназину, їхнє отримання та застосування

Also Published As

Publication number Publication date
US11179386B2 (en) 2021-11-23
US20220088006A1 (en) 2022-03-24
TW201840317A (zh) 2018-11-16
JP2023010754A (ja) 2023-01-20
JP2020510073A (ja) 2020-04-02
US20220040170A1 (en) 2022-02-10
IL269132A (en) 2019-11-28
JP7631572B2 (ja) 2025-02-18
SG11201908477QA (en) 2019-10-30
AU2022203369B2 (en) 2024-04-04
AR111182A1 (es) 2019-06-12
AU2022203369A1 (en) 2022-06-09
TWI772382B (zh) 2022-08-01
CO2019011271A2 (es) 2020-02-28
US20180263972A1 (en) 2018-09-20
EA201992168A1 (ru) 2020-03-16
KR20230003308A (ko) 2023-01-05
US20200016148A1 (en) 2020-01-16
MX2019010913A (es) 2020-01-20
BR112019018966A2 (pt) 2020-04-22
EP3596077A1 (en) 2020-01-22
ZA201906326B (en) 2022-12-21
JP7608050B2 (ja) 2025-01-06
AU2018236336A1 (en) 2019-10-24
JP2024050724A (ja) 2024-04-10
AU2018236336B2 (en) 2022-02-24
KR20200003791A (ko) 2020-01-10
UA127052C2 (uk) 2023-03-29
WO2018170214A1 (en) 2018-09-20
NZ757789A (en) 2024-08-30
CA3056612A1 (en) 2018-09-20
CN110709398A (zh) 2020-01-17
US12502385B2 (en) 2025-12-23
CL2019002629A1 (es) 2020-01-24
US11813232B2 (en) 2023-11-14

Similar Documents

Publication Publication Date Title
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
UY38602A (es) Compuestos tricíclicos condensados
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
PE20191819A1 (es) Analogos de deutetrabenazina, su preparacion y uso
CO2022017622A2 (es) Inhibidores de quinasa nek7
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
CR11857A (es) Compuestos pirazolicos 436
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
ECSP24028270A (es) Compuestos espirocíclicos
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
UY35275A (es) Derivados de aminopirazina
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
UY35535A (es) ?Derivados de fenil sulfonamidas?.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CO2022008313A2 (es) Compuestos químicos
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
CO2022019131A2 (es) Inhibidores de la quinasa nek7
MX2024003399A (es) Derivados de piridazinil-amino como inhibidores del receptor del factor de crecimiento transformante beta tipo i (alk5).
AR057162A1 (es) Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac)
UY35536A (es) ?derivados de sulfonamida?.
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla